2023-06-12 08:59:23 ET
Geron Corporation ( NASDAQ: GERN ) announced on Monday new data from its Phase 3 portion of the Phase 2/3 IMerge trial for lead candidate imetelstat in myelodysplastic syndromes (MDS) indicating a longer durability of response for the telomerase inhibitor.
According to a presentation at the European Hematology Association Annual Meeting, ~18% of patients on imetelstat in IMerge achieved one-year transfusion independence (TI) compared to ~2% on placebo (P=0.002).
That indicates ~64% of patients on imetelstat who previously achieved 24-week TI were responders according to a January data cut.
IMerge involved 178 transfusion-dependent MDS patients across North America, Europe, the Middle East, and Asia.
Regarding safety, about half of those on imetelstat experienced dose reductions due to treatment-emergent adverse events (TEAE). Less than 15% discontinued therapy due to TEAEs, with a median discontinuation period of 21.1 weeks.
At the recently concluded 2023 American Society of Hematology, Geron ( GERN ) presented data to indicate that IMerge reached the primary endpoint of 8-week TI and the key secondary endpoint of 24-week TI with statistical significance.
More on Geron
- Geron preps for commercial launch of blood cancer therapy
- Geron: Ready To Face The Competition With Imetelstat In Lower Risk Myelodysplastic Syndromes
For further details see:
Geron updates Phase 3 data for blood cancer therapy